Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

1(33.3%)

N/A

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06651177Phase 2Recruiting

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Role: lead

NCT03911466Completed

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Role: lead

NCT03911739Completed

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

Role: lead

NCT03918850Phase 3Completed

Medication Treatment for Opioid Use Disorder in Expectant Mothers

Role: lead

NCT06262347Not ApplicableCompleted

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

Role: lead

All 5 trials loaded